ADCs and their Drug Development Process

“One of the fastest-growing modalities in the pharmaceutical industry, antibody-drug conjugates (ADCs), combines a targeted antibody with a cytotoxic payload to offer numerous therapeutic benefits. Veranova’s experts have a deep understanding of the challenges involved in ADC development and have explored how advanced techniques such as preparative chromatography can help streamline the process.”

In this Q&A in Pharma Focus Europe, Veranova’s Global VP, AR&D Lab Operations, Dr. Kishore Hotha, discusses the current ADC landscape, their therapeutic potential and the challenges faced during development.

Please fill out the form below to access the download

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

First name*

Last name*

Email address*

Company*

Country*

State (if US)

Job title*

ADCs and their Drug Development Process

Veranova is your next great decision